Author details

Full Name

Charles M Perou

Affiliation

ORCID

Career Start Year

1988

Papers

429

H Index

129

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37103916	Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.	JAMA Oncol	2023
37672882	Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes.	J Clin Oncol	2023
37747807	Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors.		2023
37923752	Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.	Nat Commun	2023
37808840	Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.		2023
37574209	Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).	Clin Cancer Res	2023
37874652	Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.		2023
38046186	PAIRWISE NONLINEAR DEPENDENCE ANALYSIS OF GENOMIC DATA.	Ann Appl Stat	2023
36585450	Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.	Nat Cancer	2023
37463901	Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer.	Nat Commun	2023
37398150	Combination of Polymeric Micelle Formulation of TGFÎ² Receptor Inhibitors and Paclitaxel Produce Consistent Response Across Different Mouse Models of TNBC.		2023
36576009	HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.	J Natl Cancer Inst	2023
37137498	Gene-Expression Profiling to Decipher Breast Cancer Inter- and Intratumor Heterogeneity.		2023
37066379	Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors.		2023
37059742	Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence.		2023
36797360	Translating transcriptomic findings from cancer model systems to humans through joint dimension reduction.	Commun Biol	2023
36860655	Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals <i>TP53</i> Aneuploidy-driven Metabolic Reprogramming.	Cancer Res Commun	2023
36859416	Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer.	Nat Commun	2023
36602784	Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.	JAMA Oncol	2023
37103927	Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.	JAMA Oncol	2023
34711612	Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer.	Cancer Res	2022
36374768	HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.	EBioMedicine	2022
35653148	Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer.	Clin Cancer Res	2022
35701440	Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases.	NPJ Breast Cancer	2022
35442423	Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast Cancer.	Cancer Res	2022
36008651	Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer.	Breast Cancer Research and Treatment	2022
35437570	The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients.	Cancer Epidemiol Biomarkers Prev	2022
35418701	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women.	Sci Rep	2022
36129803	RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer.	Cancer Epidemiol Biomarkers Prev	2022
35723569	Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies.	J Natl Cancer Inst	2022
35404674	Challenges and Gaps in Clinical Trial Genomic Data Management.	JCO Clin Cancer Inform	2022
35851387	Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study.	npj Breast Cancer	2022
34990895	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.	EBioMedicine	2022
35044810	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.	J Clin Oncol	2022
35042965	Rare germline copy number variants (CNVs) and breast cancer risk.	Commun Biol	2022
34737209	TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study.	Cancer Epidemiol Biomarkers Prev	2022
34911787	Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.	Cancer Res	2022
35180770	Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics.	Cancer Research	2022
34412669	MultiK: an automated tool to determine optimal cluster numbers in single-cell RNA sequencing data.		2021
35432688	JOINT AND INDIVIDUAL ANALYSIS OF BREAST CANCER HISTOLOGIC IMAGES AND GENOMIC COVARIATES.	Ann Appl Stat	2021
35465400	Molecular analysis of TCGA breast cancer histologic types.	Cell Genom	2021
32359158	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk.	J Natl Cancer Inst	2021
31925417	SCDC: bulk gene expression deconvolution by multiple single-cell RNA sequencing references.	Briefings in Bioinformatics	2021
33479248	Inherited predisposition to breast cancer in the Carolina Breast Cancer Study.	NPJ Breast Cancer	2021
33632929	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.	Clinical Cancer Research	2021
33478572	PDGFRÎ² is an essential therapeutic target for BRCA1-deficient mammary tumors.	Breast Cancer Research	2021
34161883	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.	eBioMedicine	2021
33888599	Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident.	Science	2021
34101624	FOXA1 overexpression suppresses interferon signaling and immune response in cancer.	J Clin Invest	2021
34145248	Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells.	Nature Communications	2021